VolitionRx Announces The Publication Of A New Clinical Manuscript Demonstrating That Nucleosome Levels, As Measured By Volition's Nu.Q H3.1 And Nu.Q H3R8 Citrulline Are Elevated In People That Have Experienced A Traumatic Event And Are Even Higher In Those Patients That Go On To Have Complications From The Trauma
Benzinga Newsdesk 7 months ago
BiotechNewsGeneral
Peer Reviewed Clinical Study for Nu.Q® Biomarkers Published in Shock JournalHENDERSON, Nev., March 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company,
Peer Reviewed Clinical Study for Nu.Q® Biomarkers Published in Shock Journal
HENDERSON, Nev., March 30, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE:VNRX) ("Volition"), a multi-national epigenetics company, announces the publication of a new clinical manuscript demonstrating that nucleosome levels, as measured by Volition's Nu.Q®H3.1 and Nu.Q®H3R8 Citrulline are elevated in people that have experienced a traumatic event and are even higher in those patients that go on to have complications from the trauma.